MNG762
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.533
- TNFA_SIGNALING_VIA_NFKB+0.462
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.369
- PANCREAS_BETA_CELLS+0.324
- COAGULATION+0.270
- KRAS_SIGNALING_DN+0.240
- UV_RESPONSE_UP+0.213
- MYC_TARGETS_V2+0.209
- MYOGENESIS+0.209
- OXIDATIVE_PHOSPHORYLATION+0.204
Top 10 suppressed
- PROTEIN_SECRETION-0.427
- MITOTIC_SPINDLE-0.341
- PI3K_AKT_MTOR_SIGNALING-0.304
- PEROXISOME-0.248
- INTERFERON_ALPHA_RESPONSE-0.239
- BILE_ACID_METABOLISM-0.237
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.183
- DNA_REPAIR-0.171
- IL6_JAK_STAT3_SIGNALING-0.165
- HEME_METABOLISM-0.154
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R99 | — | — | 0.770 |
| 2 | R24 | — | — | 0.714 |
| 3 | C3L-02619 | — | cohortSQ1 | 0.688 |
| 4 | s0112232 | — | — | 0.669 |
| 5 | SRR5088843 | — | — | 0.665 |
| 6 | 82992 | EPN | Supratentorial EPN | 0.661 |
| 7 | SRR8518205 | — | E | 0.656 |
| 8 | TCGA-AN-A04A-01A-21R-A034-07 | — | C | 0.647 |
| 9 | SRR23303757 | — | — | 0.641 |
| 10 | SRR12202493 | — | — | 0.629 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.533 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.462 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.369 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.324 | Cobimetinib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.213 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.209 | Idelalisib | — uncovered |
| MYOGENESIS | 0.209 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.204 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.203 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.191 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.185 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.183 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.137 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.131 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.116 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.102 | Inavolisib | — uncovered |